After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the ...

In Q4 2024, AstraZeneca PLC (NASDAQ:AZN) was included in 14 billionaire portfolios with a total of $2.20 billion in combined ...

Plus: Comcast rolls out small-business assistance; Richie Neal takes Trump to task for tariff policies; Healey rolls out new ...

China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President Donald Trump's decision to single out the world's second-largest economy for ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca PLC closed 22.92% short of its 52-week high of £133.88, which the company reached on September 3rd.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what ...

Now may be an ideal time to buy stocks. Even if you don't have a lot of money that you can afford to invest, there are many ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...